Molecular aspects of papillary thyroid carcinoma
DOI:
https://doi.org/10.33448/rsd-v12i2.39986Keywords:
Thyroid cancer; Papillary thyroid carcinoma; Gene mutations.Abstract
Introduction: Thyroid cancer is the most common endocrine neoplasm. The pathogenesis of thyroid cancer considers mutations leading to progression through a process of dedifferentiation generating well-differentiated carcinomas, such as papillary and follicular, and progressing to poorly differentiated, undifferentiated or anaplastic thyroid carcinomas. Objective: To describe the main molecular alterations for the development of PTC. Methodology: This is a narrative review. The databases PUBMED, SCIELO, Science Direct, Google Scholar and the National Cancer Institute were used. As inclusion/exclusion criteria, articles comprised between 2004 and 2022, in Portuguese and English. Results and discussion: PTC molecular alterations arise from the initial mutation in some gene involved in the regulation of proliferation and/or cell differentiation, leading to clonal expansion of the genetically modified cell due to its ability to proliferate and escape cell cycle control through changes in genes such as BRAF, KRAS, NTRK1 and RET. Conclusion: The onset and progression of thyroid cancer comprises multiple genetic changes, including mutations that lead to activation of MAPK and PI3K-AKT signaling pathways. Altered genes that affect this pathway include mutations in genes encoding RAS and BRAF intracellular signal transducers and rearrangements in RET/PTC receptor tyrosine kinase. These data are extremely important for understanding the pathophysiological mechanism of this condition, as well as providing the basis for a more assertive diagnosis and more specific treatment, providing a more favorable prognosis with fewer side effects.
References
Abdullah, M. I., Junit, S. M., Ng, K. L., Jayapalan, J. J., Karikalan, B., & Hashim, O. H. (2019). Papillary thyroid cancer: genetic alterations and molecular biomarker investigations. International Journal of Medical Sciences, 16 (3), 450–460. https://doi.org/10.7150/ijms.29935
Acuña-Ruiz, A., Carrasco-Lopez, J., & Santisteban, P. (2022). Genomic and epigenomic profile of thyroid cancer. Best Practice & Research Clinical Endocrinology & Metabolism.https://doi.org/10.1016/j.beem.2022.101656
Brasileiro-filho, G. (2019). Bogliolo Patologia Geral. (9a ed.). Guanabara Koogan.
Cavalheiro, P. B. (2019). Câncer de tireoide: Avaliação da atividade de enzimas do sistema purinérgico, butirilcolinesterase e perfiloxidativo (Tese de doutorado, Universidade Federal de Santa Maria). Recuperado em https://repositorio.ufsm.br/handle/1/20910
Cunha, L. L. (2015). Impacto da resposta imunológica no prognóstico do paciente com carcinoma diferenciado de tiroide: da bancada à clínica (Tese de doutorado, Universidade Estadual de Campinas). Recuperado em http://repositorio.unicamp.br/acervo/detalhe/945251
Grani, G., Sponziello, M. L., Pecce, V., Ramundo, V., & Durante, C. (2020). Contemporary thyroid nodule evaluation and management. The Journal of Clinical Endocrinology & Metabolism, 105(9), 2869-2883. https://doi.org/10.1210/clinem/dgaa322
Greco, A., Miranda, C., & Pierotti, M. A. (2010). Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Molecular and Cellular Endocrinolog, 321 (1), 44-49. https://doi.org/10.1016/j.mce.2009.10.009
Instituto Nacional De Câncer -INCA. Introdução. <https://www.inca.gov.br/estimativa/introducao>
Italiano, A., Hostein, I., Soubeyran, I., Fabas, T., Benchimol, D., Evrard, S., Gugenheim, J., Becouarn, Y., Brunet, R., Fonck, M., François, E., Saint-Paul, M. C., & Pedeutour, F. (2010). KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: Biological and clinical implications. Annals of Surgical Oncology, 17(5), 1429–1434. https://doi.org/10.1245/s10434-009-0864-z
Kumar, V., Abbas, A. K., & Aster, J. C. (2018). Robbins Patologia Básica. (10a ed). Elsevier.
Lin, R., Wang, Z. X., Cottrill, E., Badjatia, N., & Gargano, S. M. (2022). Patient with multiple genetically distinct thyroid nodules including papillary thyroid carcinoma harboring novel YWHAG-BRAF fusion. Cancer Genetics, 266-267, 51–56. 10.1016/j.cancergen.2022.06.006
Matsuo, S. E., Martins, L., Leoni, S. G., Hajjar, D., Ricarte-filho, J. C. M., Ebina, K. N., & Edna, T. K. (2004). Marcadores biológicos de tumores tiroidianos. Arquivos Brasileiro de Endocrinologia e Metabologia, 48 (1), 114-125. https://doi.org/10.1590/S0004-27302004000100013
Minayo, M. C. S. (2013). O desafio do conhecimento: Pesquisa qualitativa em saúde. (14a ed.). Hucitec
Pimentel, C. P. (2018). Investigação de ocorrência de alterações moleculares nos genes KRAS, HRAS e BRAF em carcinoma papilífero de tireoide (Tese de doutorado, Universidade Federal do Pará). Recuperado em http://repositorio.ufpa.br:8080/jspui/handle/2011/9976
Riesco-Elizaguirre, G., & Santisteban, P. (2016). Advances in the molecular pathogenesis of thyroid cancer: lessons from the cancer genome. European Journal of Endocrinology, 175(5), 203-217. https://doi.org/10.1530/EJE-16-0202
Shafique, K., & Baloch, Z. (2019). Risk stratification of papillary thyroid carcinoma and its variants; from clinicopathologic features to molecular profiling. Mini-Symposium: Endocrine Pathology, 25(5), 143-153. https://doi.org/10.1016/j.mpdhp.2019.02.00
Siraj, A. K., Masoodi, T., Bu, R., Beg, S., Al-Sobhi, S. S., Al-Dayel, F., Al-Dawish, M., Alkuraya, F. S., & Al-Kuraya, K. S. (2016). Genomic profiling of thyroid cancer reveals a role thyroglobulin in metastasis. American Society of Human Genetics, 98(6), 1170-1180. https://doi.org/10.1016/j.ajhg.2016.04.014
Silveiro, S. P. & Satler, F. (2015). Rotinas em Endocrinologia. Artmed.
Sociedade Brasileira de Endocrinologia e Metabologia. (2013, maio 25). Entendendo o câncer de tireoide. https://www.endocrino.org.br/entendendo-o-cancer-de-tireoide/
Tang, K. T., & Lee, C. H. (2010). BRAF Mutation in papillary thyroid carcinoma: Pathogenic role and clinical implications. Journal of the Chinese Medical Association, 73(3), 113-128. https://doi.org/ 10.1016/S1726-4901(10)70025-3
The Cancer Genome Atlas Research Network. (2014). Integrated genomic characterization of papillary thyroid carcinoma. Cell, 159(3), 676–690. http://doi.org/10.1016/j.cell.2014.09.050
Vilar, L. & Kater, C. (2021). Endocrinologia clínica (7a ed.). Guanabara Koogan.
Volpi, E. (2021). Câncer da tireoide- Fisiopatologia, diagnóstico, tratamento e perspectivas. Europa Press Comunicação Brasil.
Xing, M. (2010). Prognostic utility of BRAF mutation in papillary thyroid cancer. Molecular and Cellular Endocrinology, 321(1), 86-93. https://doi.org/10.1016/j.mce.2009.10.012
Xing, M., Alzahrani, A. S., Carson, K. A., Viola, D., Elisei, R., Bendlova, B., Yip, L., Mian, C., Vianello, F., Tuttle, R. M., Robenshtok, E., Fagin, J. A., Puxeddu, E., Fugazzola, L., Czarniecka,A., Jarzab, B., Neill, C. J. O., Sywak, M. S., Lam, A. K., Riesco-Eizaguirre, G., Santisteban, P., Nakayama, H., Tufano, R. P., Pai, S. I., Zeiger, M. A., Westra, W. H., Clark, D. P., Clifton-Bligh, R., Sidransky, D., Ladenson,P. W., & Sykorova, V. (2013). Association between BRAFV600E mutation and mortalityin patients with papillary thyroid cancer. Jama, 309(14), 1493-1501. https://doi.org/10.1001/jama.2013.3190
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., Tolaney, S., Holt, E. H., Hui, P., Umbricht, C. B., Basaria, S., Ewertz M., Tufaro, A. P., Califano, J. A., Ringel, M. D., Zeiger, M. A., Sidransky, D., & Ladenson, P. W. (2005). BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. The Journal of Clinical Endocrinology & Metabolism, 90(12), 6373-6379. https://doi.org/10.1210/jc.2005-0987
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Ana Cristina Carneiro Mendes; Larissa Carvalho Viegas; Leila Rodrigues Danziger; Eriston Vieira Gomes
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
